Media Advisory - MedMira Inc. to launch new Rapid HIV antibody test for over-the-counter purchase in Hong Kong and Macao: Monday

Media Advisory - MedMira Inc. to launch new Rapid HIV antibody
test for over-the-counter purchase in Hong Kong and Macao: Monday 01/24/05



TORONTO, Jan. 21  /PRNewswire-FirstCall/ -- On Monday January 24th, 2005 at
6:00 am AST Canadian biotechnology company MedMira Inc. (TSX Venture Exchange:
MIR/NASDAQ: MMIRF) will officially launch a new generation of Rapid HIV
antibody tests, for over-the-counter purchase in Hong Kong and Macao. A news
release will be issued on CNW/PR Newswire at that time.

  WHO: MedMira Inc.

  WHAT: A publicly-traded Canadian biotechnology company specializing in
  rapid diagnostic tests for diseases such as HIV

  WHEN: Monday, January 24th, 2005 at 6:00 am AST

  WHERE: Hong Kong, People's Republic of China

  WHY: Company to launch an over-the-counter HIV rapid test product in the
  Hong Kong and Macao regions.

  Company Background:


MedMira is the leading global manufacturer and marketer of in vitro flow-
though rapid diagnostic tests for the clinical laboratory market. MedMira's
tests provide reliable, rapid diagnosis in just 3 minutes for the detection of
human antibodies in human serum, plasma or whole blood for diseases such as
HIV. The United States FDA and the SFDA in the People's Republic of China have
approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests,
respectively. For more information visit MedMira's website at
http://www.medmira.com/.

This news release contains forward-looking statements, which involve risk and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement. 

DATASOURCE: MedMira Inc.



CONTACT: please contact Peter Mumford, t. [phone]

x 55, c. [phone]

Copyright